Abstract:
"Partial" and "complete" CTP units are used to modify biologically active proteins and peptides to alter their clearance patterns. "Complete" CTP units have the amino acid sequence found at positions 112-118 to position 145 of the beta -subunit of human chorionic gonadotropin; "partial" CTP units are missing at least one amino acid in the region of position 118-145 inclusive. Variants of these CTP units contain 1-5 conservative amino acid substitutions which do not destroy activity. Suitable peptides or proteins which may be modified in this manner include various hormones and cytokines.
Abstract:
L'invention concerne des formes natives et mutéines de recombinaison d'hormones de reproduction humaines présentant des configurations de glycosilation caractéristiques et influençant l'activité métabolique de la protéine. L'invention concerne également des formes mutantes de recombinaison de la sous-unité alpha humaine commune à FSH, LH, CG et TSH, permettant d'obtenir des hormones présentant également des configurations de glycosilation uniques. Elle concerne en outre des matières de recombinaison permettant de produire ces sous-unités séparément ou ensemble, afin d'obtenir des hormones hétérodimères complètes dont la configuration et l'activité de glycosilation sont régulées. Des formes modifiées de sous-unités bêta LH et FSH augmentant la vitesse de dimérisation et de secrétion des dimères ou de chaînes individuelles sont décrites.
Abstract:
Single-chain forms of the glycoprotein hormone quartet, at least some members of which are found in most vertebrates, are disclosed. In one embodiment of these single-chain forms, the alpha and beta subunits of the wild-type heterodimers or their variants are covalently linked, optionally through a linker moiety. A drug may further be included within the linker moiety to be targeted to receptors for these hormones. Some of the single-chain forms are agonists and others antagonists of the glycoprotein hormone activity. Another embodiment of the single-chain compounds of the invention comprises two beta subunits of the glycoprotein hormones, which beta subunits are the same or different. These "two- beta " forms are antagonists of glycoprotein hormone activity.
Abstract:
Improved methods for recombinant production of human reproductive hormones are disclosed. These methods involve the use of animal-derived cells that contain regulated secretory granules as host cells for expression systems capable of expressing DNA encoding human reproductive hormones or their beta subunits.
Abstract:
The invention provides peptide and protein pharmaceuticals with extended half-lives. The modified peptides and proteins of the invention contain at least two tandem extensions at their C-terminus comprising the carboxy terminal portion of human chorionic gonadotropin. These "CTP units" consist essentially of the native HCG- beta sequence from position 112-118 to position 145 or conservative modifications thereof.
Abstract:
Glycosylated or nonglycosylated proteins of the formula FSHβ-(linker 1 ) n 1 -LHβ(1-X)-(linker 2 ) n 2 -α, wherein FSHß is a vertebrate follicle stimulating hormone β subunit or a variant thereof; LHβ(1-X) refers to a β subunit of a vertebrate luteinizing hormone containing positions 1-X where X is an integer of 114-121 or a variant thereof; each "linker" is a hydrophilic, flexible amino acid sequence containing 1-100 amino acid residue; each n is a 0 or 1; and α is the α subunit of a vertebrate glycoprotein hormone or a variant thereof are useful in protocols to enhance fertility in humans and in animals.
Abstract:
The invention provides recombinant native and mutein forms of human reproductive hormones with characteristic glycosylation patterns which are influential in the metabolic activity of the protein. The invention also provides recombinant mutant forms of the human alpha subunit common to FSH, LH, CG, and TSH, to obtain hormones which also have unique glycosylation patterns. Also provided are recombinant materials to produce these subunits separately or together to obtain complete heterodimeric hormones of regulated glycosylation pattern and activity. Modified forms of LH and FSH beta subunits which enhance the rate of dimerization and secretion of the dimers or individual chains are also disclosed.
Abstract:
Glycosylated or nonglycosylated proteins of the formula FSHβ-(linker1)n1-LHβ(1-X)-(linker2)n2-α, wherein FSHß is a vertebrate follicle stimulating hormone β subunit or a variant thereof; LHβ(1-X) refers to a β subunit of a vertebrate luteinizing hormone containing positions 1-X where X is an integer of 114-121 or a variant thereof; each 'linker' is a hydrophilic, flexible amino acid sequence containing 1-100 amino acid residue; each n is a 0 or 1; and α is the α subunit of a vertebrate glycoprotein hormone or a variant thereof are useful in protocols to enhance fertility in humans and in animals.
Abstract:
Single-chain agonists and/or antagonists of the glycoprotein hormones are disclosed. These proteins are of the formulae: (1) beta -(linker )m- alpha -(linker )n- beta ; or (2) beta -(linker )m- beta -(linker )n- alpha ; or (3) alpha -(linker )m- beta -(linker )n- beta , wherein each of beta and beta has the amino acid sequence of the beta subunit of a vertebrate glycoprotein hormone or a variant thereof; " alpha " designates the alpha subunit of a vertebrate glycoprotein hormone or a variant thereof; "linker" refers to a covalently linked moiety that the spaces beta and beta subunits at distances from the alpha subunit and from each other effective to retain said activity, and each of m and n is independently 0 or 1.
Abstract:
The invention provides peptide and protein pharmaceuticals with extended half-lives. The modified peptides and proteins of the invention contain at least two tandem extensions at their C-terminus comprising the carboxy terminal portion of human chorionic gonadotropin. These "CTP units" consist essentially of the native HCG- beta sequence from position 112-118 to position 145 or conservative modifications thereof.